[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521246":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":42,"responsibleParty":57,"collaborators":11,"id":60,"slug":11,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":11,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Indacaterol + mometasonefluroate","EXPERIMENTAL",null,[13,14],"Drug: Indacaterol and Mometasonefluroate (low dose)","Drug: Indacaterol and Mometasonefluroate (high dose)",{"label":16,"type":17,"description":11,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",[19],"Drug: Placebo",[21,26,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","Indacaterol and Mometasonefluroate (low dose)","Participants are administered 125 µg indacaterol + mometasonefluroate",[9],{"type":22,"name":16,"description":27,"armGroupLabels":28,"otherNames":11},"Participants are administered placebo",[16],{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Indacaterol and Mometasonefluroate (high dose)","Participants are administered 500 µg indacaterol + mometasonefluroate",[9],[34],{"name":35,"affiliation":5,"role":36},"Morten Hostrup, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":11,"email":41},"CONTACT","+4535321595","mhostrup@nexs.ku.dk",[43],{"facility":44,"status":45,"city":46,"state":11,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"August Krogh Building","RECRUITING","Copenhagen","2100","Denmark",{"type":50,"coordinates":51},"Point",[52,53],12.56553,55.67594,{"lat":53,"lon":52},[56],{"name":35,"role":39,"phone":11,"phoneExt":11,"email":11},{"type":58,"investigatorFullName":35,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Associate Professor","100521246",false,"NCT06067100","U-LABA\u002FICS Effects on Exercise Performance, Indacaterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Indacaterol","Inclusion Criteria:\n\n* Age 18-39\n* Physically active \\> 5 h weekly\n* Maximal oxygen consumption classified as high or very high\n\nExclusion Criteria:\n\n* Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist\u002Fcorticosteroid\n* ECG abnormality\n* ACQ score \\> 1.5\n* Severe bronchial hyperreactivity as determined by mannitol test\n* FEV1\u002FFVC ratio \\\u003C 0.7 determined with spirometry\n* Chronic illness determined to be a potential risk for participant during study\n* In chronic treatment with medication that may interfere with study results\n* Pregnancy\n* Smoker\n* Blood donation during the past 3 months",true,"ALL","18 Years","39 Years",{"count":71,"type":72},30,"ESTIMATED","INTERVENTIONAL",[75],"NA","The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate",[78],"Exercise Performance","2025-04-07",{"date":81,"type":82},"2025-04-09","ACTUAL",{"date":84,"type":82},"2024-01-15",{"date":86,"type":72},"2026-12-01",{"name":35,"class":6},1]